Reprioritization On Cards After Sage/Biogen’s Zurzuvae Receives CRL For MDD
Despite PPD Approval
The firms’ Zurzuvae has become the first oral drug to win US approval for postpartum depression but a thumbs down in the larger major depressive disorder indication has raised concerns that Biogen could pull out of the partnership as Sage turns its efforts to cutting costs.
